Marfan syndrome is a genetic disorder that weakens the connective tissue throughout your body. Because connective tissue acts as a structural glue holding together your bones, blood vessels, heart, eyes, and organs, the effects show up in multiple systems at once. It affects roughly 1 in 3,000 to 5,000 people, making it one of the most common inherited connective tissue disorders.
What Causes Marfan Syndrome
Marfan syndrome stems from a mutation in a single gene called FBN1, which provides the instructions for building a protein called fibrillin-1. This protein normally assembles into tiny fibers (microfibrils) that give connective tissue its strength and elasticity. When the gene is mutated, the resulting fibrillin-1 doesn’t work properly, and the structural framework of connective tissue becomes compromised.
Over a thousand different mutations in FBN1 have been linked to Marfan syndrome, which is part of why the condition varies so much from person to person. About two-thirds of cases involve a specific type of mutation called a missense mutation, where a single building block in the protein’s code is swapped for the wrong one. Beyond its structural role, fibrillin-1 also helps regulate a growth factor signaling pathway that controls how cells grow and repair tissue. When fibrillin-1 is defective, this signaling becomes disrupted, contributing to the progressive tissue changes seen in the condition.
Marfan syndrome follows an autosomal dominant inheritance pattern, meaning you only need one copy of the mutated gene to have the condition. If one parent has it, each child has a 50% chance of inheriting it. However, about 25% of cases arise from new, spontaneous mutations with no family history.
How It Affects the Heart and Aorta
The most dangerous effects of Marfan syndrome involve the cardiovascular system. More than 90% of known causes of death in people with Marfan syndrome are cardiovascular. The primary concern is progressive widening of the aortic root, the section of the body’s largest artery closest to the heart. Because the connective tissue in the aortic wall is weakened, the vessel gradually stretches under normal blood pressure. Over time, the aorta’s wall composition changes, becoming stiffer and less resilient, which accelerates the stretching.
The real danger is aortic dissection, where the inner layer of the aortic wall tears and blood forces its way between the layers. This can be fatal. To prevent it, current guidelines recommend preventive surgery when the aortic root exceeds 5 centimeters in diameter or when it’s expanding faster than 5 millimeters per year on imaging. If you have a family history of premature aortic dissection or significant valve leakage, surgery may be recommended at a smaller diameter, sometimes as low as 4.5 centimeters. People with Marfan syndrome typically get regular echocardiograms to track these measurements over time.
Skeletal Signs and Body Shape
Many people with Marfan syndrome are noticeably tall and thin with disproportionately long arms, legs, fingers, and toes. The long, slender fingers are sometimes called “arachnodactyly,” meaning spider-like fingers. Other common skeletal features include a breastbone that either pushes outward or caves inward (pectus deformity), a curved spine (scoliosis), flat feet, and joint hypermobility. Not everyone with Marfan syndrome looks the same, though. Some people have very obvious physical features while others appear relatively typical.
Eye Problems
The eyes are a major area of concern. One of the hallmark features of Marfan syndrome is lens dislocation (ectopia lentis), where the tiny fibers holding the eye’s lens in place are too weak and the lens shifts out of its normal position. This can happen in childhood and is sometimes the very first sign of the condition. Lens dislocation causes blurred vision, nearsightedness, and in some cases double vision. People with Marfan syndrome also face a higher risk of retinal detachment, glaucoma, and early cataracts.
Under the current diagnostic criteria, lens dislocation paired with aortic root widening is enough to confirm a diagnosis of Marfan syndrome even without genetic testing.
Spinal Changes
A less well-known feature is dural ectasia, a condition where the protective membrane surrounding the spinal cord (the dura) stretches and balloons outward. It occurs in roughly 63% to 92% of people who meet diagnostic criteria for Marfan syndrome, almost always in the lower back and sacral region. Many people with dural ectasia have no symptoms, but it can cause low back pain, headaches, or numbness and weakness in the legs. In one study, nerve root sleeve herniations were found in 73% of Marfan patients compared to just 1% of controls.
How Marfan Syndrome Is Diagnosed
Diagnosis follows a set of clinical criteria known as the revised Ghent nosology, developed by an international expert panel. The system puts the most weight on two cardinal features: aortic root widening and lens dislocation. If both are present and there’s no family history, the diagnosis is confirmed. When only one of these is present, doctors look for a confirmed FBN1 gene mutation or a combination of other systemic features scored on a point system that accounts for skeletal findings, skin stretch marks, dural ectasia, and other signs.
Genetic testing can identify the specific FBN1 mutation, which is particularly useful in ambiguous cases, for family screening, or when a child presents with isolated lens dislocation before other features develop.
Treatment and Medication
There’s no cure for Marfan syndrome, but treatment focuses on slowing aortic growth and preventing complications. Beta-blockers have been the standard medication since a 1994 trial showed they reduced the rate of aortic enlargement. Another class of blood pressure medication, specifically losartan (an angiotensin receptor blocker), generated excitement after animal studies suggested it might be even more effective. However, a large randomized trial published in the New England Journal of Medicine found no significant difference between losartan and the beta-blocker atenolol over three years in children and young adults. Both medications reduced the rate of aortic root growth, but neither was clearly superior.
Beyond medication, the management plan includes regular cardiac imaging (usually echocardiograms every six to twelve months), eye exams, and monitoring for spinal and skeletal changes. When the aorta reaches a critical size, elective surgical repair replaces the widened section before dissection can occur. This surgery has been one of the biggest factors in improving life expectancy.
Exercise and Activity
Because intense physical exertion raises blood pressure and puts stress on the aorta, people with Marfan syndrome are generally advised to avoid high-intensity exercise, heavy weightlifting, and competitive or contact sports. Activities like golf, bowling, walking, and moderate cycling are typically considered safe. Recent research has started to soften the blanket restriction somewhat. Studies involving structured low-intensity programs combining stationary cycling, Nordic walking, and light gymnastics have shown positive effects without worsening symptoms. There’s currently no evidence that moderate aerobic exercise or light resistance training increases mortality or accelerates aortic problems in Marfan patients, though high-intensity exercise (above about 75% of maximum capacity) has been linked to aortic complications in animal models.
Life Expectancy Today
The outlook for people with Marfan syndrome has changed dramatically. In 1972, the average lifespan for someone with untreated Marfan syndrome was about 32 years. By 1993, that number had risen to 72 years. Today, with beta-blockers, regular imaging, and elective aortic repair, life expectancy is nearly the same as the general population. Early diagnosis and consistent monitoring are what make that possible.